Program
alpha 1-Antitrypsin
Also written as “Alpha-1 MP”, “GLASSIA” and “Alpha1-proteinase inhibitor”.
Its studies are mostly in alpha 1-Antitrypsin Deficiency · Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema · Graft vs Host Disease · Diabetes Mellitus, Type 1, led by 4 companies.
Drug pageAlpha 1-Antitrypsin: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grifolsits history only | 131 open or running | phase 3since Feb 20, 2006 | Sep 12, 2005 | Sep 2028phase 3 · NCT02796937 |
| Takeda | 70 open or running | phase 4since Nov 3, 2006 | Nov 3, 2006 | none ahead |
| CSLits history only | 31 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | Sep 15, 2033phase 4 · NCT07326592 |
| Kamadaits history only | 30 open or running | phase 3since Dec 17, 2019 | Feb 24, 2011 | none ahead |
Also a collaborator on its studies: Baxalta Innovations GmbH, now part of Shire.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 3, 2006First study: phase 4 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT00396006 · 21 enrolled · Australia, New Zealand
- Jul 23, 2012Phase 4 study in alpha 1-Antitrypsin DeficiencyNCT01651351 · 30 enrolled · United States
- Aug 14, 2015Phase 3 study in alpha 1-Antitrypsin DeficiencyNCT02525861 · 34 enrolled · United States, Canada
- Mar 23, 2016Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT02722304 · 7 enrolled · United States, Australia, Canada
- Oct 24, 2016Phase 3 study in Graft vs Host DiseaseNCT02956122 · 1 enrolled · United States
- Jun 17, 2020Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT04440488
- Jun 17, 2022Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT05466747
TargetBeta
“Leukocyte elastase inhibitor”ChEMBL 37, by rule
Studies
All 7 Takeda leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05466747Pulmonary Disease, Chronic Obstructive | 4 | Withdrawn | Apr 26, 2027 | 0 |
| NCT04440488Pulmonary Disease, Chronic Obstructive | 4 | Withdrawn | Sep 12, 2025 | 0 |
| NCT02956122Graft vs Host Disease · United States | 3 | Terminated | May 3, 2018 | 1 |
| NCT02722304Pulmonary Disease, Chronic Obstructive · United States, Australia, Canada | 3 | Terminated | Sep 14, 2018 | 7 |
| NCT02525861alpha 1-Antitrypsin Deficiency · United States, Canada | 3 | Completed | Jul 29, 2020 | 34 |
| NCT01651351alpha 1-Antitrypsin Deficiency · United States | 4 | Completed | Jan 16, 2013 | 30 |
| NCT00396006alpha 1-Antitrypsin Deficiency · Australia, New Zealand | 4 | Completed | Dec 14, 2007 | 21 |
How it is read
Names in the registry
- “Alpha-1 MP”, 5 entries
- “GLASSIA”, 2 entries
- “Alpha1-proteinase inhibitor”, 2 entries
- “Alpha1-Proteinase Inhibitor (Human)”, 2 entries
- “CE1226”, 1 entry
Conditions, from the studies’ own filings
- alpha 1-Antitrypsin Deficiency, 12 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Pulmonary Emphysema, 2 studies
- Graft vs Host Disease, 2 studies
- Diabetes Mellitus, Type 1, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.